Hematology
Survival Data for Patients Younger Than 60 With Primary Myleofibrosis
Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most matu…
A quote for you...
Powered By Optimism Quotes
Adverse Events During Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis
Dr. Animesh Pardanani, Assistant Professor of Medicine and Consultant in the Division of Hematology at Mayo Clinic in Rochester, MN, Discusses his article, coauthored with Dr. Ayalew Tefferi and appearing in the December 2011 issue of Mayo Clinic Proceedings, on potential complications from withdrawal of ruxolitinib. Available at: tinyurl.com
One Thousand Patients With Primary Myelofibrosis: the Mayo Clinic Experience
Dr. Ayalew Tefferi, Consultant in the Department of Hematology at Mayo Clinic in Rochester, MN, discusses his article appearing in the January 2012 issue of Mayo Clinic Proceedings describing the Mayo Clinic experience with 1000 patients who have primary myelofibrosis and providing context for the design and interpretation of clinical… Continue reading
A Personal Perspective on CLL and Myelofibrosis Progress
Andrew Schorr shares his optimism for patients with leukemia, lymphoma, myeloma and other blood cancers, while attending the 2012 American Society of Hematology meeting in Atlanta, Georgia.
A quote for you...
Powered By Optimism Quotes
Myeloproliferative Neoplasms 2011 – Mayo Clinic
Hematologist Ruben Mesa, MD, Chair, Division of Hematology and Oncology at Mayo Clinic in Arizona, provides an update on Myeloproliferative Neoplasms
A quote for you...
Powered By Optimism Quotes
Myelofibrosis and Bone Marrow Transplant – Mayo Clinic
Ruben Mesa, MD and Veena Fauble, MD, Mayo Clinic hematologists, discuss bone marrow transplant as a treatment option for patients diagnosed with myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503
Charles Hugh-Jones, MD, Vice President, Head of Medical Oncology Affairs, Sanofi North America, discusses the results of a phase I/II study looking at SAR302503, an investigational oral JAK2-selective inhibitor for patients with myelofibrosis. The trial enrolled 59 patients; 44 with primary myelofibrosis, 12 post-polycythemia vera, and 4 post-essential thrombocythemia. 86%… Continue reading
Study Finds Ruxolitinib Effective in Reducing Myelofibrosis Symptoms – Mayo Clinic
Ruben Mesa, MD, hematologist at Mayo Clinic in Arizona, discusses findings from a study published in the New England Journal of Medicine which found Ruxolitinib effectively improves the quality of life and reduces symptoms for those with intermediate and advanced forms of myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients with Myelofibrosis.
Dr. Animesh Pardanani, Assistant Professor of Medicine and Consultant in the Division of Hematology at Mayo Clinic in Rochester, MN, Discusses his article, coauthored with Dr. Ayalew Tefferi, on potential complications from withdrawal of ruxolitinib.
Related Blogs
A quote for you...
Powered By Optimism Quotes
Myelofibrosis in 2011 – Mayo Clinic
Hematologist Ruben Mesa, MD, Chair, Division of Hematology and Oncology at Mayo Clinic in Arizona, discusses Myelofibrosis.
Related Blogs
A quote for you...
Powered By Optimism Quotes